Zenas BioPharma – Talk Bio

Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations

3 weeks ago talkbio0Tagged Amgen Uplizna, IgG4-Related Disease, Obexelimab, Phase 3 INDIGO, plunge, Zenas BioPharma

Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

4 months ago talkbio0Tagged Autoimmune Diseases, BTK inhibitor, Clinical Trials, Inhibitor, InnoCare, Interleukin-17, Multiple Sclerosis, orelabrtuinib, Pharma, TYK2 gene, Zenas BioPharma

Zenas BioPharma; InnoCare Pharma; autoimmune diseases; multiple sclerosis; BTK inhibitor; orelabrtuinib; licensing deal; clinical trials; IL-17 inhibitor; TYK2 inhibitor

Zenas BioPharma Secures $300M Royalty Deal for Obexelimab FDA Approvals

5 months ago talkbio0Tagged Approved, Autoimmune Diseases, IgG4-Related Disease, Lupus Erythematosus, Systemic, Obexelimab, Phase 3 INDIGO trial, Royalty, Royalty Pharma, United States Food and Drug Administration, Zenas BioPharma

Zenas BioPharma; Royalty Pharma; Obexelimab; autoimmune diseases; IgG4-Related Disease; Systemic Lupus Erythematosus; FDA approval; royalty agreement; Phase 3 INDIGO trial; funding